BT9 exhibits a dose- and time-dependent cytotoxic effect on medulloblastoma. by Zahra Motahari (6814013)

Effects of vidarabine, V2E, V3E and V5E on AC activity in the heart of WT and AC5KO mice. by Kenji Suita (750993)

“…<p>(A) Vidarabine (Vida), V2E, V3E and V5E similarly and significantly decreased ISO (50 µmol/L)-stimulated AC activity in the WT heart in a dose-dependent manner. …”

Comparison of the decrease of CFU in CSF and blood between treatment groups within the first 6 h after treatment. by Luca G. Valente (12463057)

Means for global competence pre- and post-test scores. by Esther Kim (2996622)

Nrf2 activation decreases PMN ROS production in response to zymosan. by Doumet Georges Helou (7255823)

Means and standard deviations of the age of mothers, fathers, and children across the seven waves. by Chiara Remondi (15301459)

Transcriptomic and metabolomic analyses of liver of <i>Fmo5</i>^<i>-/-</i> and WT mice. by Ian R. Phillips (5074121)

“…<p>(A) Volcano plot representation of differentially expressed genes (log₂-fold change) of <i>Fmo5</i>^<i>-/-</i> vs WT mice. Red dots are genes whose expression is significantly increased or decreased in <i>Fmo5</i>^<i>-/-</i> mice with a -log₁₀ <i>q</i> above 1.301 (<i>q</i> <0.05) (grey line). …”

Annual number of outpatient visits in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

“…<p>In the recurrence group, mean outpatient visits (± standard deviation) decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”

Annual treatment frequencies in all eyes. by Yasuyuki Sotani (20114144)

“…<p>The number of anti-VEGF treatments, STTA, MA-PC, PPV, and total treatments (mean ± SD) significantly decreased from 2.6 ± 1.6, 0.3 ± 0.8, 0.6 ± 0.8, 0.1 ± 0.3, and 3.7 ± 1.7 preoperatively to 0.8 ± 1.9, 0.0 ± 0.2, 0.3 ± 1.0, 0.0, and 1.2 ± 2.2; at year 2 to 0.7 ± 2.0, 0.1 ± 0.6, 0.0 ± 0.2, 0.0 ± 0.2, and 1.0 ± 2.1; and at year 3 to 0.9 ± 2.2, 0.0, 0.2 ± 1.0, 0.0 ± 0.2, and 1.1 ± 3.1 (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”

Annual number of outpatient visits in all eyes. by Yasuyuki Sotani (20114144)

“…<p>Mean visit frequency (mean ± standard deviation) significantly decreased from 11.5 ± 4.3 preoperatively to 8.8 ± 4.1, 5.0 ± 3.4, and 4.4 ± 3.2 visits in the first, second, and third postoperative years, respectively (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”

Annual treatment frequencies in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

“…Mean outpatient visits in the recurrence group decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, p < 0.001). …”

NRX-1 localization to cholinergic axons is decreased in <i>unc-104</i> mutants and colocalizes with UNC-104 in cholinergic axon terminals. by Devyn Oliver (12015660)

Depletion of <i>cyd-1</i> leads to decreased oocyte quality and increased apoptosis without affecting the DNA damage response (DDR). by Umanshi Rautela (20235283)

Effect of water content on CO₂ absorption compared to 30 wt% aqueous MEA. by Hossam K. Abdrabou (16436541)

Subjects:

TSLPR deficient mice show decreased AHR upon HDM exposure. by Latifa Koussih (326043)

Neutralization potency decreases 6-months post 2^nd vaccine but breadth and potency increase after a 3^rd vaccine dose. by Carl Graham (9415779)

Estimated mean lichen species richness vs. distance to the DMTS haul road in Cape Krusenstern National Monument, Alaska, on a log-log scale from a Bayesian posterior predictions mo... by Peter N. Neitlich (4034300)

Subjects:

The human neutrophil IL-1β secretory response, in contrast to the CXCL8/IL-8 secretory response decreases as MOI increases. by Florencia Sabbione (4862455)

HoxA9-ER directly represses <i>Cebpa</i> gene expression in myeloid cells. by Lei Peng (260321)

Differential gene expression assay EC₅₀ values in Huh-7 cells and PHH. by Xuan G. Luong (9761423)